Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

C18:1 Ceramide (d18:1/18:1(9Z))

😃Good
Catalog No. T35808Cas No. 5966-28-9
Alias Cer(d18:1/18:1(9Z)), C18:1-Ceramide

C18:1 Ceramide (d18:1/18:1(9Z)) is a ceramide, and C18:1-Ceramide levels are elevated in overweight and insulin-resistant mice and cattle, as well as in plasma and ovarian tissue of patients with advanced ovarian cancer.

C18:1 Ceramide (d18:1/18:1(9Z))

C18:1 Ceramide (d18:1/18:1(9Z))

😃Good
Purity: 99.96%
Catalog No. T35808Alias Cer(d18:1/18:1(9Z)), C18:1-CeramideCas No. 5966-28-9
C18:1 Ceramide (d18:1/18:1(9Z)) is a ceramide, and C18:1-Ceramide levels are elevated in overweight and insulin-resistant mice and cattle, as well as in plasma and ovarian tissue of patients with advanced ovarian cancer.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$35-In Stock
5 mg$79-In Stock
10 mg$127-In Stock
25 mg$255-In Stock
50 mg$397-In Stock
100 mg$653-In Stock
200 mg$916-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.96%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
C18:1 Ceramide (d18:1/18:1(9Z)) is a ceramide, and C18:1-Ceramide levels are elevated in overweight and insulin-resistant mice and cattle, as well as in plasma and ovarian tissue of patients with advanced ovarian cancer.
In vitro
Exogenous C18:1-Ceramide (5 μM, 24 h) significantly increased the survival of mouse primary retinal ganglion cells (RGCs) and reduced apoptosis induced by oxygen-glucose deprivation/reperfusion (OGD/R)[1].
In vivo
Intravitreal injection of C18:1-Ceramide (1 μL, 10 μM) in a mouse optic nerve ischemia model improved structural integrity and reduced RGC apoptosis, supporting its neuroprotective potential in ischemic retinal injury[1].
SynonymsCer(d18:1/18:1(9Z)), C18:1-Ceramide
Chemical Properties
Molecular Weight563.94
FormulaC36H69NO3
Cas No.5966-28-9
Smiles[C@@H](NC(CCCCCCC/C=C\CCCCCCCC)=O)([C@@H](/C=C/CCCCCCCCCCCCC)O)CO
Relative Density.no data available
Storage & Solubility Information
Storagekeep away from direct sunlight | store at 4°C | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMF: 80 mg/mL (141.86 mM), Sonication is recommended.
Chloroform: 4 mg/mL (7.09 mM), Sonication is recommended.
Solution Preparation Table
Chloroform/DMF
1mg5mg10mg50mg
1 mM1.7732 mL8.8662 mL17.7324 mL88.6619 mL
5 mM0.3546 mL1.7732 mL3.5465 mL17.7324 mL
DMF
1mg5mg10mg50mg
10 mM0.1773 mL0.8866 mL1.7732 mL8.8662 mL
20 mM0.0887 mL0.4433 mL0.8866 mL4.4331 mL
50 mM0.0355 mL0.1773 mL0.3546 mL1.7732 mL
100 mM0.0177 mL0.0887 mL0.1773 mL0.8866 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy C18:1 Ceramide (d18:1/18:1(9Z)) | purchase C18:1 Ceramide (d18:1/18:1(9Z)) | C18:1 Ceramide (d18:1/18:1(9Z)) cost | order C18:1 Ceramide (d18:1/18:1(9Z)) | C18:1 Ceramide (d18:1/18:1(9Z)) chemical structure | C18:1 Ceramide (d18:1/18:1(9Z)) in vivo | C18:1 Ceramide (d18:1/18:1(9Z)) in vitro | C18:1 Ceramide (d18:1/18:1(9Z)) formula | C18:1 Ceramide (d18:1/18:1(9Z)) molecular weight